{"disease":{"id":"warm-autoimmune-hemolytic-anemia","name":"warm autoimmune hemolytic anemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07019038","title":"National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia","phase":"","overall_status":"RECRUITING","enrollment_count":9999,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05786573","title":"A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Zenas BioPharma (USA), LLC","has_results":false},{"nct_id":"NCT02502903","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT04119050","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03764618","title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Rigel Pharmaceuticals","has_results":true},{"nct_id":"NCT05648968","title":"A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07039422","title":"Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03827603","title":"Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Eugene Nikitin","has_results":false},{"nct_id":"NCT01181154","title":"Rituximab in Auto-Immune Hemolytic Anemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03226678","title":"Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07324889","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Yihao Wang","has_results":false},{"nct_id":"NCT05002777","title":"Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06847607","title":"A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bing Han","has_results":false},{"nct_id":"NCT05073458","title":"Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03075878","title":"A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04661033","title":"Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT04691570","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Annexon, Inc.","has_results":false},{"nct_id":"NCT04253236","title":"To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Immunovant Sciences GmbH","has_results":true},{"nct_id":"NCT04657094","title":"Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04956276","title":"Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03965624","title":"Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05221619","title":"Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}